[EN] ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS<br/>[FR] ARYLALKYLOXYALKYLAMINES ET ARYLALKYLTHIOALKYLAMINES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES RECEPTEURS CHOLINERGIQUES NICOTINIQUES
申请人:TARGACEPT INC
公开号:WO2001016107A1
公开(公告)日:2001-03-08
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need arylalkyloxyalkylamine and arylalkylthioalkylamine compounds, including arylmethoxyalkylamines and arylmethylthioalkylamines, such as pyridylmethoxyalkylamines and pyridylmethylthio alkylamines. Exemplary compounds include methyl(3-(3-pyridylmethoxy)propyl)amine, 3-pyridyl(pyrrolidin-2-ylmethoxy)methane, methyl(1-methyl-2-(3-pyridylmethoxy)ethyl)amine, (3-((3-pyridyl)methoxy)propyl)dimethylamine, (2-((5-bromo-3-pyridyl)methoxy)ethyl)methylamine, methyl(2-((5-methoxy-3-pyridyl)methoxy)ethyl)amine, (2-((3-quinolyl)methoxy)ehtyl)methylamine, methyl(2-(pyrimidin-5-ylmethoxy)ethyl)amine, 3-((3-pyridyl)methoxy)quinuclidine, (3-pyridyl)quinuclidin-2-ylmethoxy)methane, (3-pyridyl)(pyrrolidin-2-ylmethylthio)methane and (2-((3-pyridyl)methylthio)ethyl)methylamine.